Announcement on Using Temporarily Idle Raised Funds for Cash Management
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Announcement on Using Temporarily Idle Raised Funds for Cash Management
Filed with SSE · · 4 pages · Chinese
Release
Shanghai Junshi Biosciences Co., Ltd. on 6ix
Earlier from Shanghai Junshi Biosciences
- Junshi Biosciences Announces Primary Endpoints Met in JS001sc’s Phase 3 Study for the 1ST-line Treatment of NSQ-NSCLC
- Announcement on Completion of Registration of Initial Grant under 2025 A-share Stock Option Incentive Plan
- Report for Q3 2025
- Announcement on Voluntary Disclosure of the Wholly-owned Subsidiary Passing On-site Inspection by FDA
- Announcement on Convening the Q3 2025 Performance Briefing
Later from Shanghai Junshi Biosciences
- Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 5% Scale
- Announcement on Result of Shareholding Reduction by Shareholder with Over 5% Shares
- Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients
- Junshi Biosciences Announces Acceptance of the NDA for Roconkibart (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis
- Announcement on Voluntary Disclosure of New Indication of Tuoyi® and the Inclusion of Junshida® in the National Medical Insurance Catalog
Follow Shanghai Junshi Biosciences into a list and get an email when it puts out news.
Follow Shanghai Junshi Biosciences